Abstract: An inhaler vaporizer cartridge includes a housing body with a flow channel, a liquid storage tank, and a vaporizer unit. The vaporizer unit has a wick member and heating member and is liquid-permeable such that liquid is conveyed from the tank through the vaporizer unit to the flow channel. The housing body has a cavity forming the tank and a wick member receiving chamber, and housing is divided by an intermediate wall and a flow channel section. An access opening from the receiving chamber to the flow channel is formed in the intermediate wall and covered by the heating member. Granular grains in the receiving chamber form the wick member and bear against the heating member. The grains form microchannels and are retained by a cover element. An access opening, covered with a liquid-permeable grid structure, establishes a liquid connection from the tank to receiving chamber in the intermediate wall.

Abstract: A vaporizer cartridge for an inhaler has a hollow body with a continuous flow channel and liquid storage tank. The tank has an access opening to the channel and a vaporizer unit extending over the entire access opening. The vaporizer unit has a wick member and a heating member. The vaporizer unit is liquid-permeable such that liquid is conveyed at least initially in a capillary manner from the storage tank through the vaporizer unit in the direction of the flow channel. The wick member is formed from a plurality of granular grains which, as a result of their fill and/or formation, form microchannels which establish a fluid connection between the storage tank and the flow channel, continuously from an entry side to an exit side of the wick member. An additional securing means is provided which is holds the granular wick member in position. A corresponding inhaler is also provided.

Abstract: An inhaler vaporizer cartridge includes a housing body with a flow channel, a liquid storage tank, and a vaporizer unit. The vaporizer unit has a wick member and heating member and is liquid-permeable such that liquid is conveyed from the tank through the vaporizer unit to the flow channel. The housing body has a cavity forming the tank and a wick member receiving chamber, and housing is divided by an intermediate wall and a flow channel section. An access opening from the receiving chamber to the flow channel is formed in the intermediate wall and covered by the heating member. Granular grains in the receiving chamber form the wick member and bear against the heating member. The grains form microchannels and are retained by a cover element. An access opening, covered with a liquid-permeable grid structure, establishes a liquid connection from the tank to receiving chamber in the intermediate wall.

Abstract: A vaporizer cartridge, as a component of an inhaler, has a hollow body with a continuous flow channel and a storage tank for storing liquid. The storage tank has at least one access opening to the flow channel and a vaporizer unit arranged in the region of the access opening and extending over the entire access opening. The vaporizer unit has a wick member and a heating member. The vaporizer unit is formed to be liquid-permeable such that liquid can be conveyed at least initially in a capillary manner out of the storage tank through the vaporizer unit in the direction of the flow channel. The wick member is formed from a plurality of granular grains which form microchannels as a result of their fill and/or formation. An inhaler is also provided.

Abstract: A vaporizer cartridge for an inhaler has a hollow body with a continuous flow channel and liquid storage tank. The tank has an access opening to the channel and a vaporizer unit extending over the entire access opening. The vaporizer unit has a wick member and a heating member. The vaporizer unit is liquid-permeable such that liquid is conveyed at least initially in a capillary manner from the storage tank through the vaporizer unit in the direction of the flow channel. The wick member is formed from a plurality of granular grains which, as a result of their fill and/or formation, form microchannels which establish a fluid connection between the storage tank and the flow channel, continuously from an entry side to an exit side of the wick member. An additional securing means is provided which is holds the granular wick member in position. A corresponding inhaler is also provided.

Abstract: A consumption unit for an inhaler comprises a liquid reservoir, a vaporizer device arranged in the liquid reservoir, and a vent having a flow channel extending in the liquid reservoir to a flow connection of the flow channel to the environment. The liquid reservoir comprises a filling opening, which is closed by means of a first closure part.

Abstract: A device and a method are disclosed for measuring sectional forces on a single-piece structural element in respect of a sectional plane by strain gauges, wherein a first and a second strain gauge of the plurality of strain gauges are arranged on a first outer wall, and a third and a fourth strain gauge are arranged on a second outer wall, with the result that, when the structural element is loaded with a first force, the change in length of the first and third strain gauges is opposite to the change in length of the second and fourth strain gauges, wherein the first outer wall and the second outer wall have, in the region of a cavity, at least three openings, which are separated from each other by webs, and wherein the first, second, third and fourth strain gauges are arranged on the webs.

Abstract: A device and a method are disclosed for measuring sectional forces on a single-piece structural element in respect of a sectional plane by strain gauges, wherein a first and a second strain gauge of the plurality of strain gauges are arranged on a first outer wall, and a third and a fourth strain gauge are arranged on a second outer wall, with the result that, when the structural element is loaded with a first force, the change in length of the first and third strain gauges is opposite to the change in length of the second and fourth strain gauges, wherein the first outer wall and the second outer wall have, in the region of a cavity, at least three openings, which are separated from each other by webs, and wherein the first, second, third and fourth strain gauges are arranged on the webs.

Abstract: The present invention relates to vaccine compositions comprising a nucleic acid encoded by an equine arterivirus virus (EAV) open reading frame (ORF) 2 nucleic acid, and a nucleic vector comprising said EAV ORF 2. The invention further relates to the methods and kits encompassing the use of EAV ORF 2 containing vaccine compositions and nucleic acid vectors for the prevention and/or treatment of EAV infections.

Abstract: The present invention relates to vaccine compositions comprising a nucleic acid encoded by an equine arterivirus virus (EAV) open reading frame (ORF) 2 nucleic acid, and a nucleic vector comprising said EAV ORF 2. The invention further relates to the methods and kits encompassing the use of EAV ORF 2 containing vaccine compositions and nucleic acid vectors for the prevention and/or treatment of EAV infections.

Abstract: Disclosed are vaccine compositions comprising open reading frame (ORF) 2, ORF 5 and ORF 7 nucleic acid of EAV, and vectors comprising said ORFs. Also disclosed are methods of using the ORFs and vectors in the manufacture of a medicament for the prevention and treatment of EAV infections.

Abstract: The invention relates to a method of pre-clinical and clinical diagnosis of transmissible spongiform encephalopathies, characterised in that the altered expression of a marker protein is measured. In particular embodiments, in the method according to the invention, the marker protein measured is the prion protein PrP-sen or interferon gamma (IFN&ggr;) or the laminin receptor (LR) or the laminin receptor precursor (LRP). The invention also relates to a test kit using antibodies specific to the marker protein according to the invention. The invention further relates to a test kit using oligonucleotides which are capable of hybridising under stringent conditions with the nucleic acid coding for the marker protein according to the invention. The invention further relates to the use of antibodies or oligonucleotides which are specific for the above-mentioned marker proteins in a method according to the invention.

Abstract: The invention relates to a method of pre-clinical and clinical diagnosis of transmissible spongiform encephalopathies, characterised in that the altered expression of a marker protein is measured. In particular embodiments, in the method according to the invention, the marker protein measured is the prion protein PrP-sen or interferon gamma (IFN&ggr;) or the laminin receptor (LR) or the laminin receptor precursor (LRP). The invention also relates to a test kit using antibodies specific to the marker protein according to the invention. The invention further relates to a test kit using oligonucleotides which are capable of hybridising under stringent conditions with the nucleic acid coding for the marker protein according to the invention. The invention further relates to the use of antibodies or oligonucleotides which are specific for the above-mentioned marker proteins in a method according to the invention.